Epitel's™ Remote EEG Monitoring System's (REMI™)
DeviceAmbulatory electroencephalography (EEG) monitoring
NCT Number: NCT06027749
The goal of this clinical trial is to test Epitel's™ Remote EEG Monitoring System's (REMI™) ability to record electroencephalography (EEG) of seizure events in an ambulatory setting for extended periods (14 - 28 days) in patients presenting with questionable seizure characterization. The main questions it aims to answer are: • Can more seizure events be recorded in fourteen (14) days than can be recorded in three (3) days? • Do treating clinicians find clinical value in extended fourteen (14) - twenty-eight (28) days of EEG? Participants will wear a portable EEG device (REMI) for fourteen (14) to twenty-eight (28) days in their home/community setting.
Interested in participating?
Request Info18 year–70 year
All sexes
Interventional
Not applicable
University of South Florida, Tampa, Florida, United States
This is a prospective study to quantify Epitel's™ Remote EEG Monitoring System's (REMI™) ability to record electroencephalography (EEG) of seizure events in an ambulatory setting for extended periods (14 - 28 days). Patients presenting with questionable seizure characterization that are scheduling a conventional at home ambulatory EEG (Amb EEG) and who meet the study inclusion and exclusion criteria will be prescribed a REMI system.
The purpose of this study is to demonstrate that the REMI system is able to record EEG data that clinicians can use to identify ictal events over extended periods, and that extended clinical EEG data is valuable in the diagnosis and treatment of seizure related symptoms.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Ambulatory electroencephalography (EEG) monitoring
Time frame: Fourteen (14) days
Epileptiform seizure activity as identified by three independent board-certified epileptologists assessing data collected by REMI. The number of seizures identified in the first three days will be compared to the number of seizures identified during days one (1) to fourteen (14).
Time frame: Twenty-eight (28) days
Epileptiform seizure activity as identified by three independent board-certified epileptologists assessing data collected by REMI. The number of seizures identified in the first fourteen (14) days will be compared to the number of seizures identified during all twenty-eight (28) days.
Epitel, Inc.
Industry
Impact of Capturing Ictal Events With Ultra-long-term Ambulatory EEG Monitoring With REMI.
Acronym: REMI
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05864547
Brain Diseases, Cardiovascular Diseases
Trondheim, Norway
View Trial DetailsNCT05140265
Brain Diseases, Central Nervous System Diseases
Albuquerque, New Mexico, United States
View Trial DetailsNCT03478852
Brain Diseases, Central Nervous System Diseases
Bethesda, Maryland, United States
View Trial DetailsNCT07234695
Abnormalities, Multiple, Alzheimer Blood Biomarkers
Granada, Andalusia, Spain
View Trial Details